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Abstract
Background
Genome-wide association studies (GWAS) have identified several loci associated with schizophrenia
and/or bipolar disorder. We performed a GWAS of psychosis as a broad syndrome rather than within
specific diagnostic categories.
Methods
1239 cases with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder; 857 of their
unaffected relatives, and 2739 healthy controls were genotyped with the Affymetrix 6.0 single
nucleotide polymorphism (SNP) array. Analyses of 695,193 SNPs were conducted using UNPHASED,
which combines information across families and unrelated individuals. We attempted to replicate
signals found in 23 genomic regions using existing data on nonoverlapping samples from the
Psychiatric GWAS Consortium and Schizophrenia-GENE-plus cohorts (10,352 schizophrenia patients
and 24,474 controls).
Results
No individual SNP showed compelling evidence for association with psychosis in our data. However, we
observed a trend for association with same risk alleles at loci previously associated with schizophrenia
(one-sided p = .003). A polygenic score analysis found that the Psychiatric GWAS Consortium’s panel of
SNPs associated with schizophrenia significantly predicted disease status in our sample (p = 5 × 10 )
and explained approximately 2% of the phenotypic variance.
Conclusions
Although narrowly defined phenotypes have their advantages, we believe new loci may also be
discovered through meta-analysis across broad phenotypes. The novel statistical methodology we
introduced to model effect size heterogeneity between studies should help future GWAS that combine
association evidence from related phenotypes. Applying these approaches, we highlight three loci that
warrant further investigation. We found that SNPs conveying risk for schizophrenia are also predictive
of disease status in our data.
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psychosis, schizophrenia
Psychotic disorders including schizophrenia, bipolar disorders, and schizoaffective disorders affect
approximately 3% of the general population (1–6) and constitute the most severe forms of mental
diseases. Characteristic symptoms include hallucinations, delusional beliefs, and severe mood variations
and cognitive impairments, all of which can lead to major changes in behavior and ability to function.
According to the World Health Organization’s World Health Report, these psychotic disorders are
ranked within the top seven leading causes of disability in young adults (7).
The genetic architecture of schizophrenia and bipolar disorder has been shown to include common
alleles of subtle effect and rare mutations of large effect, often involving genome copy number variation
(8–11). Recent large-scale meta-analyses of schizophrenia (12), conducted by the Psychiatric GWAS
Consortium (PGC), combined data from more than 50,000 individuals from 17 international cohorts
(13–25) and identified seven associated loci. Of these loci, five were new, and two had been previously
implicated. The strongest new finding in schizophrenia was within an intron of a putative primary
transcript for MIR137 (microRNA 137), a known regulator of neuronal development. Four other
schizophrenia loci with strong statistical support contain predicted targets of MIR137, suggesting
MIR137-mediated dysregulation as a previously unknown etiologic mechanism in schizophrenia. The
meta-analysis (12) also confirmed the role of the major histocompatibility complex (MHC) region, as
suggested in other studies (23,24,26,27), as well as a marker in intron four of transcription factor 4
(TCF4) (24).
The PGC conducted a similar meta-analysis for bipolar disorder (28) including more than 11,000 cases
and 51,000 controls from previous association studies (15,29–41). The analysis confirmed an
association with CACNA1C and identified a new intronic variant in ODZ4. An overlap in the polygenic
component between schizophrenia and bipolar disorder was also found (42,43). In a combined meta-
analysis of both schizophrenia and bipolar disorder, three loci reached genome-wide significance:
CACNA1C, ANK3, and the ITIH3-ITIH4 region (28).
As data accumulate, there is increasing evidence for overlap in the genetic component to risk between
different psychiatric disorders (44–46). When combined with epidemiologic and neuroimaging data
(47–50), the shared genetic architecture supports the view of schizophrenia, bipolar disorder, and other
psychoses as related rather than etiologically distinct entities (8,12,28,46,51–59). Motivated by these
findings, we performed a genome-wide association study (GWAS) of psychotic disorders including
patients with schizophrenia, schizoaffective disorder, and bipolar disorder with a history of psychotic
symptoms.
Methods and Materials
The Cohort
Before any exclusion, the full data set included 6935 participants with 1820 patients, 1224 of their
unaffected relatives, and 3891 healthy control subjects. These samples were collected through seven
centers across Australia and Europe (Germany, Holland, Spain, and United Kingdom). Participants
provided written informed consent, and the study was approved by the respective ethical committees at
each of the seven participating centers. After quality control, the full sample included 4835 participants
of which 1239, 857, and 2739 were patients, their unaffected relatives, and healthy control subjects,
respectively. Additional sample and center details are provided in Table S1 of Supplement 1.
Inclusion and Exclusion Criteria and Phenotype Definition
To allow for a DSM-IV (60) diagnosis to be ascertained or ruled out, all participants (including controls
and unaffected family members) underwent a structured clinical interview with either the Schedule for
Affective Disorders and Schizophrenia or the Structured Clinical Interview for DSM Disorders, or the
Schedules for Clinical Assessment in Neuropsychiatry (61–63). Of the cases passing quality control, 784
met criteria for schizophrenia, 113 for bipolar disorder with a history of psychotic symptoms, 110 for
psychotic disorder not otherwise specified, 97 for schizophreniform disorder, 64 for schizoaffective
disorder, 44 for brief psychotic disorder, 20 for delusional disorder, and 7 for substance-induced
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psychosis. Participants in all groups were excluded if they had a history of neurologic disease or head
injury resulting in loss of consciousness.
DNA Sample Preparation
Genomic DNA obtained from blood for all participants was sent to the Wellcome Trust Sanger Institute,
Cambridge, United Kingdom. Samples were processed in 96-well plate format and each plate carried a
positive and a negative control. DNA concentrations were quantified using a PicoGreen assay
(Invitrogen, Life Technologies, Grand Island, New York) and an aliquot assayed by agarose gel
electrophoresis. A sample passed quality control if the original DNA concentration was at least 50 ng/µL
and the DNA was not degraded.
Genotyping Methodology and Quality Control
To track sample identity, 30 single nucleotide polymorphisms (SNPs) including sex chromosome
markers were typed on the Sequenom platform before entry to the whole genome genotyping pipeline.
Of the initial 6935 samples, 347 failed quality control due to degraded or insufficient DNA or incorrect
sex classification. The remaining samples were sent for genotyping with the Genome-wide Human SNP
Array 6.0 at Affymetrix Services Lab (http://www.affymetrix.com).
Data Quality Control
See Tables S2 and S3 in Supplement 1. Genotype calling was conducted using the CHIAMO algorithm
(64,65) modified for use with the Affymetrix 6.0 genotyping array. We excluded 11,610 SNPs with a
study-wide missing data rate over 5%. We removed 26,858 SNPs with four or more Mendelian
inheritance errors identified with Pedstats (66). Additional exclusion criteria were departure from
Hardy-Weinberg equilibrium (p < 10 ) or minor allele frequency (MAF) <.02 with 2404 and 145,097
SNPs removed, respectively. A total of 38,895 SNPs from the X or Y  chromosomes or mitochondrial
DNA were also excluded from the analysis. Finally, 9499 poorly genotyped SNPs were removed
following visual inspection of the genotyping intensity plots in the program Evoker (67).
We excluded 214 samples with more than 2% missing data across all SNPs. Another 70 samples were
excluded due to divergent genome-wide heterozygosity (inbreeding coefficients were F > .076 or F <
−.076 as estimated with PLINK (42). Chromosomal sharing was inferred from a genome-wide subset
of 71,677 SNPs and from each duplicate pair the sample with the most complete genotype data was
kept. We removed 70 duplicates and monozygotic twins by excluding one of each pair of individuals
showing identity by descent greater than 95%.
After quality control, 4835 individuals remained. Initial analysis of the genotype data identified a high
fraction of samples (approximately 30%), which showed poor signal-to-noise ratio in the genotyping
assay. Because the experimental source of the problem was unclear and to ensure a robust set of
genotype calls, these samples were removed from further analysis. We note that the sample loss was
randomly distributed across the three clinical groups (32% of patients, 30% of relatives, and 30% of
controls; χ  (2 df) = 3.2; p = .20). Full details on the sample quality control are provided in Table S2 of
Supplement 1.
In addition to 3490 unrelated individuals, there were 1345 related individuals clustered in 462 families.
The family size ranged between 2 and 5 with an average of 2.9 members. Of the families, 196 were
control families, 243 had one affected case only, 21 families included two cases, and another 2 families
had three cases. Data from these individuals were analyzed at 695,193 autosomal SNPs.
Population Structure Analysis
To investigate the genetic structure in the data, we performed principal component (PC) analysis (PCA)
of unrelated individuals using EIGENSOFT version 3.0 (68) on a thinned set of SNPs (see Methods and
Materials in Supplement 1). Owing to the multicenter nature of our study, we assessed the need to
include PCs as covariates in statistical tests of association to control for population stratification (69).
This was done by using PLINK (42) to calculate the genome-wide distribution of the association test
statistic in the unrelated individuals using different numbers of PCs as covariates. Possible inflation in
the test statistic was measured by the genomic control parameter λ, which is the ratio of the median of
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the observed test statistic distribution to that of its expectation under the null hypothesis (70).
Association Analysis in Our Discovery Sample
A genome-wide association analysis was conducted with UNPHASED v3.1.4. (71), which allows a
combined analysis of both families and unrelated individuals, thus increasing statistical power.
UNPHASED calculates separately the transmitted and untransmitted alleles in families as well as the
allelic frequencies in unrelated patients and controls, giving a combined odds ratio, 95% confidence
interval, and p value. The analysis included three PCs as covariates.
For SNPs showing association with psychosis in our data with p < 1 × 10 , proxy SNPs were identified
using the proxy report routine in PLINK (42). Only those SNPs that were in linkage disequilibrium (r
≥ .5) with and within 100-kb distance from at least one such proxy SNP that showed association with
psychosis with p < 1 × 10  were selected for the replication phase. These criteria reduced the possibility
that the association signal was driven by an artifact at the most associated SNP.
We attempted to replicate 44 SNPs included in the catalogue of published GWAS (72), accessed in
January 2012, for schizophrenia or bipolar disorder with p values less than 1 × 10 . These SNPs and
the studies that identified them are listed in Table 1. If a reported SNP was not genotyped directly in our
data, we used the 1000 Genomes Project (73) data to identify the best tag (highest r ) and orientated
the haplotype to the risk allele so that the directions of the odds ratios were matched between our
analysis and the previous studies. Where relevant information was not available, the SNP was excluded
from analysis.
Related Effects Meta-Analysis
We attempted in silico replication with independent samples from the PGC and the SGENE+ consortia
using both a fixed effects meta-analysis (42) and a Bayesian related effects approach (27). The Bayesian
related effects model (see Methods and Materials in Supplement 1) was considered appropriate in this
context because there are obvious sources of heterogeneity between the discovery and the replication
datasets due to differing phenotype definitions and sample origins. To ensure that no samples were
overlapping between the discovery and replication data sets, we used a subset of at least 13,000 SNPs to
exclude 717 participants (51 cases, 642 controls, 24 relatives) from our primary study. Similarly,
another 74 control subjects were excluded from the SGENE+ replication cohort. Only SGENE+
samples that were not part of the PGC study were included in our meta-analyses.
Polygenic Score Analysis
A polygenic score analysis was conducted using a thinned (on the basis of linkage disequilibrium) panel
of 113,774 SNPs from the PGC-schizophrenia meta-analysis. Of these SNPs, 72,635 were available in
our data, and we further added suitable proxies for another 19,434 SNPs, which were identified through
the program SNAP (75) to have r  > .9 with the index SNP and to be within 500-kb distance. Of 4835
samples passing the above described quality control filters we excluded 717 individuals that overlapped
with the PGC sample and another 833 related participants. Therefore, our polygenic analysis was based
on a subset of 3285 unrelated subjects comprising of 1188 patients and 2097 controls. The polygenic
score for each individual was calculated from the number of risk alleles they carried for each SNP,
weighted by the log(OR) provided by the PGC, and summed across all the SNPs. Calculations were
performed using the PLINK SNP scoring routine (42).
We used logistic regression, with the three population structure PCs and the center of origin of the
samples as covariates, to test whether the polygenic scores were predictive of case–control status in our
study. Following Purcell et al. (26), we reported the proportion of the variance of disease risk in our
sample (as measured by Nagelkerke’s pseudo-R ) that could be explained by the panel of SNPs. We
examined the proportion of the variance explained by our data at various p value thresholds for the
PGC-schizophrenia SNP list (p < .01, .05, .1, .2, .3, .4, and .5) (26,43).
Results
The primary goal of our study was to use published GWAS data in schizophrenia and bipolar disorder to
facilitate discovery in a new sample with a broad psychosis phenotype. First, we examine previously
−4
2
−2
−7
2
2
2
3/25/2014 A Genome-wide Association Analysis of a Broad Psychosis Phenotype Identifies Three Loci for Further Investigation
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3923972/?report=printable 5/23
published loci in our data set. We then present our discovery association data followed by replication in
independent samples, using a novel meta-analysis approach. Finally, we report a polygenic score
analysis testing whether a panel of SNPs associated specifically with schizophrenia are predictive of the
broader phenotype in our sample.
Population Structure
Analysis of our data via PCA showed that the major components of the genetic variation capture the
geographic origin of the samples (Figure S1 in Supplement 1). The first PC separates samples from
northern Spain (Santander) from the rest of the sample. We found it necessary to include the first three
PCs as covariates to control for the confounding effects of population structure even though this may
reduce power to detect associations. The genomic control parameter, λ, was equal to 1.030 and 1.374
with and without including the three PCs respectively.
Replication of Previously Published Loci in Our Data Set
To ascertain the strength of association in our data at loci previously associated with schizophrenia
and/or bipolar disorder, we systematically assessed the evidence at the SNPs most strongly correlated
with the previously reported SNPs and their risk alleles (Table 1; Figure 1)
(12,15,21,23,24,26,28,30,33,34,37,38,66,76–96). We observed evidence for association at several loci.
These include multiple SNPs in the MHC region, most strongly at rs9272219 near HLA-DQA1. We also
replicated association at MIR137, MCTP1, NRGN, and CDC68. More generally, we observed a positive
correlation between previously reported effect sizes and those estimated here, most notably with
schizophrenia associated loci where 19 of the 24 loci had the same risk allele (one-sided p = .003). We
note that this sign test remained significant (p < .05) after thinning to reduce correlation between SNPs
and removing the SNPs within the MHC (Table S4 in Supplement 1).
Association Analysis in Our Discovery Sample
We did not identify any novel SNPs associated with psychosis as a broad phenotype with p < 1 × 10
from our data set. Figure 2 and Figure S2 in Supplement 1 show respectively the quantile-quantile plots
of the distribution of observed and expected p values and the Manhattan plot of all autosomal SNPs that
passed quality control.
Independent Replication of Our Discovery Data
We selected 63 SNPs in 23 genomic regions (Supplementary Data in Supplement 1) showing the
strongest evidence for association in our discovery dataset (p < 1 × 10 ) and having at least one
suitable proxy SNP also associated (see Methods and Materials). We then attempted in silico replication
using the large independent (see Methods and Materials) data sets publicly available from the PGC
(51,57,97,98) as well as with data provided by the SGENE+ Consortium (24,25).
All of the selected 63 SNPs were present in at least one of the replication data sets, and 53 SNPs were
available in both collections giving a two-study independent replication data set with 10,352 patients
and 24,474 control subjects. By combining estimates of the logarithmic odds ratios weighted by their
precision (i.e., inverse variance of the estimator) across discovery and replication cohorts, we conducted
a three-study meta-analysis with 11,540 patients, 833 of their unaffected relatives, and 26,571 control
subjects. Table 2 contains the SNPs that in the replication data showed an effect in the same direction
(with one-sided p < .05) as in the discovery data set and had either combined (discovery plus
replication) fixed effects p value < 10  or combined fixed effects or related effects Bayes factor >100.
Regional association plots of these SNPs are included in Figure 3 and forest plots are given in Figure S3
in Supplement 1. Full details of the replication meta-analyses are presented in Supplement 1.
Two of five top regions in our discovery analysis, rs743393 (on chromosome 3) and rs968794 (on
chromosome 7), showed effects in the same direction in the replication data with one-sided replication p
values of .020 and .007, respectively. However, the combined fixed effects evidence of association at
these loci is weak by the standards of GWAS (p values 7 × 10  and 8 × 10 , and Bayes factors 25 and
200, respectively). Bayes factors from the related effects model (440 and 7400, respectively), which
allow heterogeneity in effect size across studies, are larger than those from the fixed effect model but
–7
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still fail to provide convincing levels of evidence for these associations. See Wellcome Trust Case Control
Consortium (66) for interpreting Bayes factors in the GWAS context.
Polygenic Score Analysis
We performed a polygenic score analysis using the SNPs associated with schizophrenia in the PGC
study. Logistic regression analyses showed significantly higher scores for patients than control subjects
(p = 5 × 10 ), and explained approximately 1.7% of Nagelkerke’s pseudo-variance in our sample. For
additional results on the polygenic component, see Methods and Materials and Figure S4 in Supplement
1.
Discussion
Although extensive twin research has shown high heritability estimates ranging between 73% and 85%
for schizophrenia, schizoaffective disorder, and manic syndromes (99–103), compared with other
neuropsychiatric diseases, the search for psychosis susceptibility genes has not been straightforward
(104–110). Several loci have now been convincingly identified, and more are expected to be found
through the PGC, a large international collaboration undertaking mega-analyses of the available data
(8,12,28). In this context, our sample with 4835 participants has modest power to detect new variants
unequivocally (111), and thus it is not that surprising that we did not identify convincing novel
associations with a broad psychosis phenotype. For example, our data provide less than 10% power at
type I error of 1 × 10  for an allelic relative risk of 1.2 at a common SNP, and in practice power may
be further reduced because of our broader disease phenotype and our use of PC covariates to control for
population structure. It has been estimated that for allelic odds ratios of 1.1 and 1.2 as many as 10,000
to more than 20,000 subjects would be required to achieve 80% power at genome-wide significance
levels (112). We hope that our data set will be valuable in the future meta-analyses that are likely to
identify further common variants for psychotic illnesses with convincing statistical evidence.
The loci for which we found the best evidence of association, given our data and the independent
replication samples from the PGC and SGENE+ consortium, are reported in Table 2 and their regional
association plots are in Figure 3. These include rs743393 located in chromosome 3, which is near the
Integrin alpha 9 gene (ITGA9), thought to codify for a membrane glycoprotein that mediates cell-cell
and cell-matrix adhesion (22). SNP rs968794 in chromosome 7 is close to the NDUFA4 gene coding for
a protein that is involved in the mitochondrial membrane respiratory chain (23). Finally, rs4761708 is
located in a gene desert in chromosome 12 flanked by recombination hotspots. Limited information is
available on the role of these genes and whether they are causal in increasing the risk of developing
psychosis. Additional data are required to confirm the associations and to inform on underlying disease
mechanisms.
Although our sample was too small to identify new loci unequivocally, it had good power to replicate
previously published signals with modest effects assuming they are consistent across psychosis
phenotypes. The analysis of established schizophrenia loci shows that there is a trend for consistent
association in our data (Figure 1). Also the polygenic score analysis showed that, compared with control
subjects, our cases are enriched for alleles thought to convey risk for schizophrenia; the PGC’s panel of
SNPs significantly predicted case–control status in our study and explained around 2% of the
phenotypic variance in our sample. This is comparable to previously reported figures in other European
case–control and family-based populations (26,43) and is consistent with a highly polygenic model of
disease risk. Larger data sets are required to determine whether these signals are specific to only some of
the subphenotypes of psychosis or are present across them.
Schizophrenia and bipolar disorder are thought to be highly complex and polygenic, with potentially
thousands of susceptibility genes of small effect and, particularly for schizophrenia, also with rare
variants of larger effects (10,14,26,52,58,107,110–113). Previous GWAS have generally targeted a
specific diagnostic category, and the merit of analyzing a psychosis spectrum is debatable. One of the
challenges facing psychiatric genetics has been the heterogeneity of the diseases in question and
studying a broader phenotype could exacerbate this problem. However, as GWAS data accumulate,
there is growing evidence of genetic overlap between schizophrenia and bipolar disorder
(8,12,28,44,46,51,55,56,58–60). Therefore, in addition to examining narrowly defined diseases it is of
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use to undertake cross-disorder analyses. Our replication of established schizophrenia hits in a broadly
defined psychosis sample and polygenic analyses support this view.
Current benchmarks for establishing new associations usually insist on a combined discovery and
replication p value of less than 5 × 10  using a fixed effects meta-analysis, which is the correct
summary of the overall statistical evidence when the true effect size is exactly the same across the
studies. However, when the effect size may genuinely differ between the studies due to, for example,
differences in phenotype definition, patterns of linkage disequilibrium or environmental contributions, it
is appropriate to assess association evidence with a model that allows for heterogeneity. Here we have
used a Bayesian related effects model that assumes that the effects between the studies are similar (e.g.,
highly correlated on the log odds scale) but not necessarily the same. A computational advantage of this
model is that it only requires the studywide summary statistics (effect size and its standard error), and
therefore we believe it will be useful in future meta-analyses of existing GWAS data sets, for example,
across neuropsychiatric diseases.
In our study, we applied the related effects model to combine the discovery and replication results at 63
SNPs that had the most evidence in the discovery analysis. As expected, the related effects model assigns
a higher probability than the fixed effects model to the event that these SNPs represent real associations
(Supplement 1). For any one SNP, this can be either because the association is a true positive but
heterogeneous and/or subject to a “winner’s curse” effect (114,115) or because the association is a false
positive and appears heterogeneous because of a relatively strong discovery signal created by chance
effects. Future studies are needed to determine conclusively whether the SNPs reported in Table 2 and 
Figure 3 represent real associations.
The scenario described here in which a discovery analysis of a particular phenotype in a small sample
attempts to replicate putative associations in silico, in much larger meta-analyses of similar phenotypes,
is likely to become more common in human genetics as GWAS data accumulate. We note that stringent
p value thresholds for combined discovery and replication meta-analysis make it challenging to identify
new loci because loci with consistent effects across studies will have already been identified. Therefore,
an ongoing genome-wide meta-analysis across related phenotypes modeling effect heterogeneity where
appropriate is arguably the most powerful approach to identify additional susceptibility loci.
In conclusion, although no individual SNPs reached convincing evidence of association with psychosis,
our data contribute to the international effort to produce a cohort large enough to investigate both the
shared and separate genetic bases of multiple psychotic disorders. Our polygenic score analysis indicates
that the PGC-derived panel of SNPs conveying risk specifically for schizophrenia is also predictive of
case–control status in our data, explaining around 2% of the phenotypic variance. We advocate the use
of related effects models in large meta-analyses for summarizing the evidence for association across
independent studies of related phenotypes.
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Figures and Tables
Figure 1
Replication of prev iously  published associated schizophrenia (SCZ) and bipolar disorder (BPD) loci. Reported
odds ratios from the literature (x  axis) plotted against the odds ratios estimated from our data as listed in 
Table 1  (y  axis). The dotted line indicates an odds ratio of 1  in our data. Points above the line indicate the same
direction of effect in prev ious studies and our data. Black circles indicate single nucleotide poly morphisms that
replicate (p one-sided < .05) in our study . Triangles denote single nucleotide poly morphisms within the major
histocompatibility  complex  region. Sign tests for an enrichment of effect in the same direction are presented for
loci prev iously  associated with schizophrenia, bipolar disorder, or both. Additional details on the sign tests are
available in Table S4 of Supplement 1 .
Figure 2
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Quantile-quantile plots of the distribution of observed and expected p value at all autosomal single nucleotide
poly morphisms passing quality  control. The genomic control lambda value was 1 .03. This represents analy ses
conducted on our entire discovery  sample (n = 4835).
Figure 3
Regional association plots for the three single nucleotide poly morphisms (SNPs) reported in Table 2. The plots
show the ev idence of association in our discovery  data at genoty ped SNPs. The SNP listed in Table 2 is indicated
with a diamond, and flanking SNPs (circles) are colored according to their correlations (r ) with this SNP
measured in HapMap. CEU, Utah residents (CEPH) with Northern and Western European ancestry .
Table 1
Evidence in Our Discovery Data at Loci Previously Reported to Be Associated with SCZ and/or BPD
Chr Position Genes SNP Risk OR Phen Previous Best T ag r  1000 Freq p Value
2
2
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(b36) Allele Studies Genom es (T wo-
Sided)
1 98502934 MIR137 rs162557 9-T 1.12 SCZ (12) rs17 82810 .97 5 .8034 .0641257
1 167 90307 9 BRP44,
DCAF6
rs10489202-
A
1.23 SCZ (21) rs10489202 1.000 .2312 .310317
1 243608967 — rs67 03335-G 1.09 SCZ (12) rs67 03335 1.000 .4324 .47 6216
2 58222928 VRK2 rs2312147 -C 1.09 SCZ (24,7 5) rs1518395 1.000 .617 2 .7 40698
2 193984621 PCGEM1 rs17 662626-
A
1.2 SCZ (12) rs17 666314 .633 .942 .810016
3 36862980 — rs4624519-T 1.09 SCZ (12) rs4624519 1.000 .6264 .7 0907 2
3 52821011 ITIH1, NEK4 rs10427 7 9-
A
1.19 BPD (38,7 6) rs10427 7 9 1.000 .6237 .357 295
3 52855229 ITIH3, ITIH4 rs2239547 -T 1.1 SCZ (12) rs157 3815 .7 86 .7 67 8 .28307 8
3 1805507 02 FXR1 rs67 82299-T 1.1 SCZ (26) rs67 82299 1.000 .7 294 .822086
4 103457 418 NFKB1 rs230529-T 1.45 SCZ (7 7 ) rs230529 1.000 .3895 .363959
5 94154588 MCTP1 rs17 418283-
C
1.21 BPD (38) rs255339 .834 .2968 .0838988
6 27 143883 MHC rs13194053-
T
1.22 SCZ (23,26) rs7 7 45603 .866 .7 697 .1037 31
6 27 248931 MHC rs6932590-T 1.16 SCZ (24,26,7 8,7 9) rs6938200 .87 4 .7 947 .21997 4
6 28227 604 MHC,NKAPL rs1635-G 1.28 SCZ (80) rs2299030 .909 .03693 .265435
6 3017 4131 MHC,TRIM26 rs20217 22-C 1.15 SCZ (12) rs2517 611 1 .000 .8058 .418896
6 3217 2993 MHC,
NOTCH4
rs3131296-G 1.19 SCZ (24,7 8) rs207 127 8 1.000 .8534 .61264
6 32602269 MHC, HLA-
DQA1
rs927 2219-G 1.14 SCZ (23) rs927 2219 1.000 .7 105 .07 407 7 1
6 897 32101 GABRR1 rs1220167 6- 1 .31 SCZ, (81) rs1220167 6 1.000 .2452 .211557
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C BPD
7 145959243 CNTNAP2 rs802568-C 2.03 SCZ,
BPD
(81) rs802568 1.000 .027 46 .197 092
7 156048649 LOC393076 rs10949808-
T
1.27 SCZ,
BPD
(81) rs10949808 1.000 .397 .224947
8 4180844 CSMD1 rs10503253-
A
1.16 SCZ (12) rs10103330 1.000 .1993 .807 814
8 38031345 LSM1,
WHSC1L1
rs16887 244-
A
1.19 SCZ (21) rs16887 244 1.000 .7 614 .4367 7 1
8 58840924 FAM110B rs1992045-T 1.56 SCZ,
BPD
(81) rs1992045 1.000 .07 363 .125349
8 897 60311 MMP16 rs7 004633-
A
1.11 SCZ (12,82) rs7 005110 1.000 .1925 .914021
9 121359286 ASTN2 rs117 89399-
G
1.29 SCZ,
BPD
(81) rs117 89399 1.000 .4962 .4157 83
10 6217 9812 ANK3 rs10994336-
T
1.45 BPD (33,38,83–86) rs3808943 .858 .05389 .2097 58
10 6227 9124 ANK3 rs10994397 -
T
1.22 BPD (28) rs3808943 .858 .05389 .2097 58
10 1047 7 5908 CNNM2 rs7 914558-G 1.22 SCZ (12,87 ) rs105097 57 1.000 .5927 .1317 29
10 104906211 NT5C2 rs11191580-
T
1.2 SCZ (12,87 ) rs11191580 1.000 .9169 .912034
11 17 160148 — rs4356203-G 1.09 SCZ (12) rs4356203 1.000 .4236 .342312
11 66551002 Multiple rs10896135-
G
1.12 BPD (28) rs4930390 1.000 .2557 .901194
11 7 907 7 193 ODZ4 rs1257 67 7 5-
G
1.14 BPD (28) rs7 932890 1.000 .17 37 .259849
11 98125404 CNTN5 rs2509843-C 1.27 SCZ,
BPD
(81) rs2848547 1.000 .37 11 .400322
11 124606285 NRGN rs12807 809-
T
1.15 SCZ (24,80,89) rs1939214 .97 2 .8282 .0051205
12 2345295 CACNA1C rs10067 37 -
A
1.18 SCZ,
BPD
(15,33,37 ,38,90) rs10067 37 1.000 .3265 .353821
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12 2419896 CANCNA1C rs47 65913-A 1.14 BPD (28) rs47 65914 .935 .8061 .432068
13 42653437 DGKH rs1012053-A 1.59 BPD (91–93) rs117 0188 .806 .8133 .26017
13 106651661 DAOA rs4996815-C 1.28 SCZ,
BPD
(82) rs4996815 1.000 .357 6 .7 37 436
15 38995491 Multiple rs12899449-
A
1.2 BPD (33) rs12899449 1.000 .7 063 .441365
16 23634026 Multiple rs420259-A 2.08 BPD (34,66,94,95) rs420259 1.000 .7 306 .517 7 01
18 527 52017 CCDC68 rs12966547 -
G
1.4 SCZ (12) rs1187 47 16 1.000 .567 .037 9359
18 53058238 TCF4 rs17 594526-
T
1.44 SCZ (26) rs17 594526 1.000 .0321 .9157 97
19 193617 35 NCAN rs1064395-A 1.17 SCZ,
BPD
(30,96) rs1064395 1.000 .1639 .543254
20 19852503 RIN2 rs6046396-G 1.28 SCZ,
BPD
(82) rs6046396 1.000 .3015 .57 124
Evidence for association at the best marker, as measured by correlation (r ) in the 1000 Genomes
Project data (74), of previously implicated loci. Where the previously reported single nucleotide
polymorphism was not typed in our data, we oriented the haplotypes to estimate the odds ratio for the
risk allele allowing a one-sided comparison.
BPD, bipolar disorder; Chr, chromosome; CI, confidence interval; Freq, frequency; OR, odds ratio;
Phen, phenotype; SCZ, schizophrenia.
One-sided p < .05 (for replication with the same risk allele).
Table 2
Loci Where the Strongest Evidence of Association Was Found
Chr SNP (Risk
Allele)
Position
(Build 36)
Discovery  p OR
(95% CI)
Replication p
OR (95% CI)
Com bined p OR
(95% CI)
log10BF
Sam e
log10BF
Related
3 rs7 43393-C 37 7 1897 2 9.40E-06 .039 7 .40E-04 1.43 2.64
1.301  (1 .157 –
1.462)
1 .043 (1 .002–
1.085)
1 .067  (1 .028–
1.108)
7 rs9687 94-A 10856010 8.30E-07 .014 8.40E-05 2.3 3.87
1.324 (1 .184–
1.480)
1 .050 (1 .010–
1.091)
1 .07 6 (1 .037 –
1.116)
12 rs47 617 08-
C
9227 6217 1.40E-04 .024 6.40E-04 1.56 2.18
1.291  (1 .130–
1.47 6)
1 .058 (1 .007 –
1.110)
1 .083 (1 .034–
1.133)
2
a
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Evidence of association across the discovery sample and the Psychiatric GWAS Consortium and SGENE
replication collections as also shown as a forest plot in Figure S3 in Supplement 1. We report p values,
ORs (and 95% CIs) for these cohorts and the combined evidence (using an inverse variance weighted
fixed effects approach). We also show the log10BF for models assuming effects to be either the same
(fixed) or related (allowing heterogeneity). Note that the discovery sample ORs and p values presented
in this table are based on a subset of our sample that did not overlap with the replication cohorts;
therefore, the p values may vary from those presented in Figure S2 in Supplement 1, which includes our
entire discovery data set.
BF, Bayes factor; Chr, chromosome; CI, confidence interval; OR, odds ratio; SNP, single nucleotide
polymorphism.
